Dublin-domiciled specialty pharmaceuticals company Mallinckrodt is to create 45 highly-skilled jobs as part of a €45 million investment.

The company is to establish a new manufacturing facility at the College Business and Technology Park in Blanchardstown, Dublin 15.

The development will provide 300 jobs during the two-year construction phase and 45 skilled positions once the facility is completed.

The new development is to include a two-storey manufacturing building, a three-storey administration building and additional areas for future investment on a c.4.85 hectare site.

Mallinckrodt, which has its headquarters in Mulhuddart, Dublin 15 but operates from its location in Missouri in the US, is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Mallinckrodt was spun-off by Covidien in 2013.

The company, which currently employs more than 120 people at its existing manufacturing site and offices in Dublin, said it has invested more than €165 million in Ireland over the past 22 years.

"We are proud to have had a significant presence in Ireland for over two decades, and today marks an important step for the company. Our Irish workforce has served as a tremendous asset to our global operations to date. We are particularly pleased to be making this sizeable capital investment today, continuing our long-standing operations in Ireland," said Mallinckrodt chief executive and president Mark Trudeau.